Conclusion of non-exclusive discount contracts under § 130a paragraph 8 of the German Civil Code V for medicines with the active substance omalizumab (R03DX05) within the period from 1.8.2021 to 31.7.2023 with the possibility of concluding a contract at any time (open-house model).

The AOK Rhineland-Palatinate/Saarland — The Health Fund offers discount contracts with the active substance omalizumab (R03DX05) to all interested pharmaceutical companies without a selection decision. Contracts are concluded within the framework of an “open house model”. The contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Rhineland-Palatinate/Saarland — Die Gesundheitskasse. In the open house model, uniform conditions apply to all participants. Contract content, conditions and access procedures are uniform — individual negotiations are not conducted.

The contract terms are a maximum of 24 months, and the earliest start of the contract is August 1, 2021. All contracts end no later than 24 months after the date of the earliest start of the contract, regardless of the date of the respective contract conclusion. Joining or concluding a contract can be made at the first of each month within the 24-month period.

There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.

The AOK Rheinland-Pfalz / Saarland - Die Gesundheitskasse reserves the right to replace the non-exclusive open house discount agreements with exclusive discount agreements within the framework of Europe-wide tendering procedures during the contract period. With the entry into force of advertised, exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically.

Interested pharmaceutical companies can request participation documents and contract documents from the contact address mentioned under I.1). Contracts for the active substance omalizumab (R03DX05) will be concluded for the first time with effect from 1.8.2021. Interested parties wishing to become a contractual partner on this date must submit the contract documents to AOK Rhineland-Palatinate /Saarland — Die Gesundheitskasse by June 30, 2021. It depends on access at AOK Rhineland-Palatinate/Saarland - Die Gesundheitskasse.

Note: The first award in this procedure will be granted no earlier than 10 calendar days after the publication of this EU announcement in the Official Journal. Later contracts can be concluded on the first day of each month during the 24-month maximum term. For interested parties who would like to become contractual partners on these follow-up dates, the receipt of the contract documents including Appendix 1 must be submitted no later than the end of the month preceding the previous month of the desired start of the contract (e.g. receipt April 30th when the contract starts June 1st). The exact entry deadlines will be announced with the contract documents. This publication is not a public contract within the meaning of the procurement coordination directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.